

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)



(10) International Publication Number
WO 2021/191305 A1

(51) International Patent Classification:

A61K 31/18 (2006.01) A61K 31/573 (2006.01)
A61K 31/426 (2006.01) A61K 31/616 (2006.01)
A61P 11/00 (2006.01) A61K 31/635 (2006.01)
A61P 31/14 (2006.01) A61K 31/7052 (2006.01)
A61K 31/167 (2006.01) A61K 31/706 (2006.01)
A61K 31/431 (2006.01) A61K 31/727 (2006.01)
A61K 31/496 (2006.01) A61K 38/20 (2006.01)
A61K 31/546 (2006.01) A61K 45/06 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2021/057624

(22) International Filing Date:

24 March 2021 (24.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20166073.5 26 March 2020 (26.03.2020) EP
20211370.0 02 December 2020 (02.12.2020) EP

(71) Applicant: **DOMPE' FARMACEUTICI SPA** [IT/IT];
Via Santa Lucia 6, 20121 MILANO (IT).

(72) Inventors: **ALLEGRETTI, Marcello**; c/o DOMPE' FARMACEUTICI SPA, Via Campo di Pile, snc, 67100 L'AQUILA (IT). **MANTELLI, Flavio**; c/o DOMPE' FARMACEUTICI SPA, Via Campo di Pile, snc, 67100 L'AQUILA (IT). **PIEMONTE, Lorenzo**; San Raffaele Scientific Institute, Via Olgettina 60, 20132 MILANO (IT).

(74) Agent: **MAURI, Elisabetta Maria Ester**; c/o DOMPE' FARMACEUTICI SPA, Via Santa Lucia 6, 20121 MILANO (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19

(57) Abstract: The present invention relates to CXCL8 inhibitors for use in the treatment of COVID-19 patients with pneumonia.



WO 2021/191305 A1